INCR - InterCure estimates Q4 revenue growth 3 times from prior year
InterCure (NASDAQ:INCR) estimates Q4 prelim revenue to be over C$31M, three times greater than the year ago quarter and 24% higher from previous quarter; FY21 revenue of C$87M (+250% Y/Y). It is expected to see eighth consecutive quarter of high double-digit growth representing an annualized run rate of C$124M. The company expects continued increases in operating profit, EBITDA and net profit during the quarter. The company exceeded one-ton medical cannabis products dispensed per month during the quarter, which represents ~30% market share of Israel's medical cannabis. Q4 results are scheduled for Mar.15 release.
For further details see:
InterCure estimates Q4 revenue growth 3 times from prior year